相关实验视频

Updated: Mar 17, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

HER2-低与HER2-阴性乳腺癌的比较预后:一个元分析

Yuanyuan Li¹, Tao Chen¹, Chuangang Tang²

¹The Xuzhou Clinical College of Xuzhou Medical University, Jiangsu, 221009, China.

Anti-cancer agents in medicinal chemistry

|March 15, 2026

概括

与HER2-阴性BC相比,HER2-低乳腺癌 (BC) 的总生存率 (OS) 改善,但病理完整反应 (PCR) 降低. 在这次元分析中,这些群体之间的无疾病生存率 (DFS) 并没有显著差异.

科学领域:

在瘤学瘤学.
翻译研究是翻译研究.
生物标志物发现发现

背景情况:

新兴的抗体 - 药物结合体 (ADC) 突出了人体表皮生长因子受体2 (HER2) 低表达作为乳腺癌 (BC) 的潜在治疗标.
目前关于HER2-低BC的预后意义的证据有限,尽管正在进行新的ADC的临床试验.

研究的目的:

进行系统的元分析,比较HER2-低与HER2-阴性乳腺癌患者的生存结果的预后值.
评估HER2低状态对整体存活率 (OS),无病存活率 (DFS) 和病理完整响应 (PCR) 率的影响.

主要方法:

我们对科克伦图书馆和PubMed进行了系统的搜索,以确定23项符合条件的回顾性或前性研究.
来自781,941名HER2-低BC患者的数据使用随机效应模型进行了聚合,以计算OS和DFS的危险比率 (HR) 和PCR的几率比率 (OR).
OS是主要终点,DFS和PCR率作为次要终点.

主要成果:

与HER2-阴性BC患者相比,HER2-低BC患者的生存状况显著改善 (HR = 0.82,P = 0.001).
在HER2-低和HER2-负BC组之间没有观察到DFS的显著差异 (HR = 0.87,P = 0.28).
与HER2-阴性BC相比,HER2-低BC患者的PCR率明显较低 (OR = 0.88,P < 0.001).与HER2-阴性BC相比,HER2-低BC患者的PCR率明显较低.

结论:

在乳腺癌中,低HER2状态与显著增加的整体存活率有关,但与HER2-负状态相比,病理完整反应率降低.
与HER2-阴性患者相比,HER2-低乳腺癌患者的无病生存率没有显著增加.

关键词:

低HER2水平的乳腺癌.在HER2阴性乳腺癌.这是一个元分析.预后. 预后. 这是一个预后.幸存率幸存率生存率

更多相关视频

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...